OrbiMed’s Relay Therapeutics RLAY Stock Holding History

OrbiMed’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-501,966	Closed	-$4.22M	–	129
2023 Q3	$4.22M	Buy	+501,966	New	+$5.4M	0.09%	103
2021 Q3	–	Sell	-350,000	Closed	-$12.8M	–	184
2021 Q2	$12.8M	Hold	350,000	–	–	0.13%	113
2021 Q1	$12.1M	Hold	350,000	–	–	0.11%	116
2020 Q4	$14.5M	Hold	350,000	–	–	0.13%	114
2020 Q3	$14.9M	Buy	+350,000	New	+$13.3M	0.19%	98

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

OrbiMed's RLAY Position: Q4 2023 in Review

OrbiMed sold out of Relay Therapeutics (RLAY) in Q4 2023, closing a stake of 501,966 shares — an estimated $4.22M sold.

OrbiMed first reported a position in RLAY in Q3 2020 and held it in 5 quarters. The position peaked at $14.9M in Q3 2020. 177 funds tracked by Wall St. Rank hold RLAY as of Q4 2023.

OrbiMed reported no remaining Relay Therapeutics position as of Q4 2023 after selling out during the quarter.
OrbiMed sold 501,966 Relay Therapeutics shares in Q4 2023, an estimated $4.22M.
OrbiMed first reported a position in Relay Therapeutics in Q3 2020 and held it in 5 quarters.
OrbiMed's Relay Therapeutics position peaked at $14.9M in Q3 2020.
177 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2023.

Based on OrbiMed's 13F filing for Q4 2023, filed 14 Feb 2024.